Cannabis, Cannabinoids, and Endocannabinoids
Herausgeber: R Martin, Colin; Patel, Vinood B.; Preedy, Victor R
Cannabis, Cannabinoids, and Endocannabinoids
Herausgeber: R Martin, Colin; Patel, Vinood B.; Preedy, Victor R
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Cannabis, Cannabinoids, and Endocannabinoids offers a comprehensive reference on natural and synthetic cannabinoids, providing coverage on both adverse and non-adverse effects, including reactivity to pain, changes in behavior and neuroactivity. This volume updates on research on the effects of these compounds in brain function and neurological dysfunction, offering readers a comprehensive reference on medical usage and the symptom relief provided by these compounds. With coverage of neurological diseases like Alzheimer's and Parkinson's, and a wide range of other afflictions, including…mehr
Andere Kunden interessierten sich auch für
- Nutrition and Neurological Disorders563,99 €
- Norman DoidgeThe Brain's Way of Healing17,99 €
- Veronica O'KeaneA Sense of Self: Memory, the Brain, and Who We Are16,99 €
- Frederick EarlsteinGuillain-Barre Syndrome: Diagnosis, Symptoms, Treatment, Causes, Doctors, Autoimmune Disorders, Prognosis, Research, History, and More!15,99 €
- David J LindenTouch22,99 €
- Christopher DecharmsTwo Views of Mind: Abhidharma and Brain Science17,99 €
- Qing YuBiologically Active Peptides in Invertebrates68,99 €
-
-
-
Cannabis, Cannabinoids, and Endocannabinoids offers a comprehensive reference on natural and synthetic cannabinoids, providing coverage on both adverse and non-adverse effects, including reactivity to pain, changes in behavior and neuroactivity. This volume updates on research on the effects of these compounds in brain function and neurological dysfunction, offering readers a comprehensive reference on medical usage and the symptom relief provided by these compounds. With coverage of neurological diseases like Alzheimer's and Parkinson's, and a wide range of other afflictions, including depression, anxiety, nausea and cancer, this broad coverage expounds on the physiological, psychological and pharmacological effects of these compounds. Unique case reports are also provided, creating a platform for research on the use of these compounds in improving patient care, brain function and neurological dysfunction. As the endocannabinoid system has been implicated in various neurological conditions, this book is a welcomed resource on the topics presented.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Elsevier Science Publishing Co Inc
- Seitenzahl: 570
- Erscheinungstermin: 13. Oktober 2023
- Englisch
- Abmessung: 285mm x 225mm x 40mm
- Gewicht: 2096g
- ISBN-13: 9780443187599
- ISBN-10: 0443187592
- Artikelnr.: 66275319
- Verlag: Elsevier Science Publishing Co Inc
- Seitenzahl: 570
- Erscheinungstermin: 13. Oktober 2023
- Englisch
- Abmessung: 285mm x 225mm x 40mm
- Gewicht: 2096g
- ISBN-13: 9780443187599
- ISBN-10: 0443187592
- Artikelnr.: 66275319
Cannabis Use, Neurobiology, Psychology, and TreatmentI. Setting the scene
and introductory chapters1. Metabolomics of the cannabis plant; 2. The
roots of Cannabis sativa: chemical and pharmacological profile; 3. Cannabis
related compounds in beverages and food; 4. The impact of prenatal cannabis
exposure: an overview; 5. Cannabinoid Genotoxicity and Congenital
Anomalies: A Convergent Synthesis of European and USA Datasets; 6. Cannabis
Genotoxicity and Cancer Incidence: A Highly Concordant Synthesis of
European and USA Datasets; 7. Cannabis, Cognitive impairment and Car Crash
risk
II. Cannabis usage8. Recreational cannabis use: a French perspective of
adverse effects; 9. Acute and chronic impact of cannabis on human
cognition; 10. Polydrug users, use of cannabidiol (CBD) and abuse
potential/Polydrug users, use of cannabinoids and abuse potential; 11.
Cannabis stigmas: a narrative of features; 12. Alterations of THC and CBD
ratios and impact on cognition; 13. When cannabis is used for medicinal
purposes: a focus on back pain
III. Pharmacological and Physiological Aspects14. Cannabis, cannabinoids
and receptor responses; 15. Cannabidiol (CBD): abuse potential and
withdrawal; 16. 4,5- Dihydro-1H-pyrazole/3,4-Diarylpyrazoline class of
cannabinoid-1 (CB1R) receptor antagonists and their potential in medicinal
applications
IV. Neurobiology of cannabis17. Neurobiology of cannabis; 18. The
kynurenine pathway, neurobiology and cannabis misuse: a new narrative; 19.
Central nervous system cancers and use of cannabis and related products: an
updated narrative; 20. Chronic cannabis users: links with glutamate and
resting state connectivity; 21. Brain metabolic responses to cannabis use
in people with multiple sclerosis: Insights from [18F]-FDG positron
emission tomography and functional MRI; 22. Genetic Variation and Acute
Responses to Cannabis; 23. Cell Signaling of the CB1 Cannabinoid Receptor
via beta-arrestins, Cannabinoid Receptor Interacting Protein (CRIP1a) and
other regulatory proteins; 24. Cannabis and impact on memory: from in utero
to adults; 25. Central CB1 receptors and age-related changes: investigating
the effects of DELTA-9-tetrahydrocannabinol; 26. Alcohol, cannabis and
visual memory
V. Neurobiology of cannabinoids27. The role of Delta-FosB in the plasticity
of the cannabinoid system; 28. Functional profile of synthetic cannabinoid
receptor agonists: exploring cannabinoid and non-cannabinoid targets; 29.
Linking the G protein-coupled orphan receptor GPR55 to the cannabinoid
receptors (CB1 and CB2): a new narrative; 30. Proteomic analysis of
cannabinoids in human oligodendrocytes; 31. Cannabinoids and
endocannabinoid signaling at the basal forebrain cholinergic system; 32.
Cannabidiol (The major non-psychotropic cannabinoid in the cannabis plant)
and the PI3K/Akt pathway in the CNS; 33. Effects of cannabidiol and other
phytocannabinoids on ion channels;34. Cannabis, neurodevelopment and the
"two-hit hypothesis"
VI. New and synthetic cannabinoids35. Impact of tetrahydrocannabinol (THC )
and synthetic "spice"cannabinoids on nicotine use and abuse; 36. Synthetic
cannabinoids: how do they compare to DELTA9-tetrahydrocannabinol:
neurological effects and beyond
VII. Biomarkers, analysis and screening37. The DSM-5 criteria of cannabis
use disorder: methods and applications; 38. Cannabis and clinical high risk
for psychosis: monitoring and smartphones
VIII. Impact on non-neurological systems39. The impact of cannabis and
cannabinoids on the skin; 40. Cannabis consumption in reproduction and
teratogenicity; 41. Cannabis compounds and putative cytotoxicity: profile
of cancer cells
IX. Treatments, strategies and resources42. Motivational Interviewing for
Cannabis Use Disorders: a narrative review from research to practice; 43.
An Overview of Current Pharmacologic Interventions for Management of
Cannabis Withdrawal and the Evidence for Their Use; 44. Managing
cannabinoid hyperemesis syndrome in paediatrics: A new narrative review;
45. Gabapentinoids for the Treatment of Cannabis Use Disorder: A Focus on
Human Laboratory Research; 46. Treating psychosis in users of synthetic
cannabinoids
X. Resources47. Cannabis and Web based Resources
Medicinal Usage of Cannabis and CannabinoidsI. Setting the scene and
introductory chapters1. How medical cannabis may influence the future of
medicine; 2. Medical cannabis and cannabinoids: how best to extract
components from plant material; 3. Medicinal usage of cannabis and its
impact on mental health among cancer patients and survivors; 4. Cannabis
sativa as a traditional phytomedicine: a new narrative covering different
countries; 5. Medical use of cannabis in the middle east; 6. What medicinal
cannabis is used for: a focus on Canada; 7. New York perspectives of
medical cannabis laboratory analysis; 8. Epigenetic regulations on the
quality of clonal cannabis plants: secondary metabolites and profiles; 9.
Aberrant use of medicinal cannabis: theoretical and empirical
considerations; 10. Profile of older users of medical cannabis and
cannabinoids; 11. Use of cannabidiol oil by caregivers: a focus on
Alzheimer's disease; 12. Medicinal use of cannabis: adverse events as a
balanced perspective
II. Physiological aspects and metabolic aspects13. Physiopathology and use
of cannabinoids for fibrotic diseases; 14. Cannabinoids in inflammation and
atherosclerosis; 15. Targeting the CB(2) receptors and other
endocannabinoid elements to delay disease progression in cardiovascular
diseases; 16. BMI in cannabis users: regulation, mechanisms and public
health impact
III. Neurological, psychological and behavioural aspects17. Neuroprotection
by cannabis related products, cannabidiol and cannabigerol, and associated
mechanisms of action; 18. Cannabis terpenes as neuroprotective agents: a
focus on alpha-bisabolol; 19. Cannabidiol in medicinal usage of stress:
modelling investigations into cocaine; 20. Medicinal cannabis and
neurocognition impairment; 21. Genetic models of audiogenic seizures: what
they are and how cannabinoids and Cannabis-derived compounds can be used to
alleviate their symptoms - an updated narrative; 22. Addressing the
validity of cannabinoid therapy as an option for the treatment of substance
use disorder
IV. Pharmacological and cellular aspects23. Cannabidiolic acid (CBDA),
features and profiles: anti-hyperalgesic effects; 24. Cannabis-drug
interactions: implications for medicinal cannabis use; 25. Cannabinoid
receptor subtype 2 (CB2R): features and targets for medical applications;
26. Medical use of cannabidiol and impact on cancer cell viability; 27.
Anti-inflammatory and antioxidant and immunomodulatory effects of
phytocannabinoid -caryophyllene: A mechanistic overview
V. Symptom Control and Medicinal Uses28. Cancer patients and providers:
Attitudes and beliefs of cannabis and cannabinoids use as a treatment; 29.
CBD (cannabidiol) use in breast cancer chemotherapy; 30. Sleep: cannabis
and cannabinoids use; 31. Cannabis and cannabis related products and their
uses in aiding sexual health of men and women; 32. Symptom control in
palliative care settings: The role of cannabis-based medicines; 33.
Cannabidiol (CBD) Use in Fragile X Spectrum Disorders; 34. Hempseed
(Cannabis sativa) and ameliorative effects in hypercholesterolemia; 35.
Benzodiazepines and cannabis use; 36. Features of
(+)-trans-cannabidiol-2-hydroxy pentyland applications to disease: a focus
on usage in diabetic nephropathy; 37. Medical use of cannabis: applications
to Tourette syndrome; 38. Cannabinoids and their use in chronic non-cancer
pain: a new narrative review; 39. Endometriosis: features and potential
role of medical cannabis; 40. Cannabis usage for Crohn's disease and
ulcerative colitis: a narrative; 41. Medical cannabis and use in migraine;
42. Cannabidiol (CBD ) and potential in medicinal use in rheumatoid
arthritis; 43. Role of Cannabinoids in Glaucoma: Lowering Intraocular
Pressure or Neuroprotection; 44. Medicinal potential of anandamide as a
representative endocannabinoid and its effect at the cellular level in skin
VI. Resources45. Medical Cannabis and Resources
Neurobiology, Physiology, And The Endocannabinoid SystemI. Setting the
scene and introductory chapters1. Distribution of the endocannabinoid
system: linking signalling and development; 2. The endocannabinoid system,
immunomodulation, and LPS-induced inflammation; 3. Physiology of the
endocannabinoid systems: imaging and the use of positron emission
tomography (PET); 4. The endocannabinoid system and aging; 5. The
endocannabinoid system and post traumatic stress disorder (PTSD): a new
narrative
II. Neurobiology of the endocannabinoid system6. The protective effect of
the endocannabinoid system in neurotoxin induced damage to hippocampal
neurons: a focus on light and electron microscopy; 7. Endocannabinoid
Signaling and excitatory and inhibitory synapses; 8. The endocannabinoids
and potassium channels: an updated narrative; 9. Social interactions and
neural activity: linking cellular studies and endocannabinoid signalling;
10. Exercise and Parkinson's disease: linking in the cannabinoid type 1
(CB1) and type 2 (CB2), and mu-opioid receptors; 11. The endocannabinoids
system and endocannabinoid receptors in sleep; 12. Endocannabinoids and
inhalant misuse: neuropsychological aspects; 13. Fatty acid amide hydrolase
(FAAH) in substance use disorders: FAAH regulation and inhibition in
cannabis, alcohol, nicotine, stimulant, and opioid use disorders; 14.
Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and
human soluble epoxide hydrolase (sEH) enzyme inhibitors: interlinking the
endocannabinoid system; 15. WWL70: linking the hydrolyses
2-arachidonoylglycerol, endocannabinoid and eicosanoid pathways:
therapeutic potential and neurological disease; 16. Endocannabinoid
catabolic enzyme inhibitors and pain alleviation; 17. The endocannabinoid
system in health and disease: features in epilepsy; 18. The endocannabinoid
system and autoimmune demyelination: a focus on multiple sclerosis; 19.
Endocannabinoid signaling and the lateral habenula; 20. On the interplay
among endocannabinoid, noradrenergic and glucocorticoid systems: evidence
from aversive memory studies
III. Receptor biology and responses 21. Adenosine A2A-cannabinoid CB1
receptor heteromers in the brain: From trans-inhibition to
trans-activation; 22. Hippocampal CB1, CB2 receptors, the endocannabinoid
system and fear memory; 23. Beta-caryophyllene, the CB2 cannabinoid
receptor-specific agonists and wound healing; 24. The nigrostriatal
dopaminergic pathway: impact of WIN 55212-2 as a potent cannaboinoid
receptor agonist; 25. Peripheral cannabinoid receptor 1 antagonists and
impact on adipocytes; 26. Endocannabinoid system receptors in plasma
membranes : extraction, lipid rafts and the cortex; 27. Applications to
wound healing: cannabinoid receptor 1 antagonism and collagen deposition;
28. Role of the Transient Receptor Potential Vanilloid 1 (TRPV1), a
component of the endocannabinoid system, in anxiety, depression, and
cocaine addiction; 29. Allosteric modulators of the endocannabinoid system:
Org27569 and cannabinoid receptor 1 (CB1); 30. Naturally occurring
DELTA-9-tetrahydrocannabinol-derivatives and binding to CB1 and CB2
receptors: Linking in the endocannabinoid system
IV. Profiles and behaviour of selective endocannabinoids31. New cannabinoid
receptor type 1 and 2 agonists and applications to understanding the
endocannabinoid system; 32. Fatty acid amide hydrolase, the endocannabinoid
anandamide and neurological disease; 33. The endocannabinoid-system in the
immuno-biology of dendritic cells; 34. Palmitoylethanolamide and other
anandamide congeners in neuroinflammation-based disorders: linking in the
endocannabinoid system; 35. Endocannabinoid modulation of synaptic function
and behavior in the dorsomedial hypothalamus; 36. Key role of anandamide
and the endocannabinoid system in the modulation of cardio-renal
homeostasis; 37. The endocannabinoid system: Signaling and social
motivation
V. Exogenous, synthetic other compounds linking in the endocannabinoid
system38. Safety and toxicology of the dietary cannabinoid
beta-caryophyllene; 39. Synthetic cannabimimetics: an overview
VI. Compartive studies in non neurological systems 40. Non Neurological
Aspects of the Endocannabinoid System: Non Alcoholic Fatty Liver Disease;
41. Components of the Endocannabinoid system: Hepatic expression levels of
the cannabinoid receptors and microRNAs; 42. Tumour growth and the
endocannabinoid system: investigating CB2 agonists; 43. Linking
Endocannabinoid System, Palmitoylethanolamide and Sarcopenia in view of
therapeutic outcomes
VII. Resources44. Endocannabinoids and Resources
and introductory chapters1. Metabolomics of the cannabis plant; 2. The
roots of Cannabis sativa: chemical and pharmacological profile; 3. Cannabis
related compounds in beverages and food; 4. The impact of prenatal cannabis
exposure: an overview; 5. Cannabinoid Genotoxicity and Congenital
Anomalies: A Convergent Synthesis of European and USA Datasets; 6. Cannabis
Genotoxicity and Cancer Incidence: A Highly Concordant Synthesis of
European and USA Datasets; 7. Cannabis, Cognitive impairment and Car Crash
risk
II. Cannabis usage8. Recreational cannabis use: a French perspective of
adverse effects; 9. Acute and chronic impact of cannabis on human
cognition; 10. Polydrug users, use of cannabidiol (CBD) and abuse
potential/Polydrug users, use of cannabinoids and abuse potential; 11.
Cannabis stigmas: a narrative of features; 12. Alterations of THC and CBD
ratios and impact on cognition; 13. When cannabis is used for medicinal
purposes: a focus on back pain
III. Pharmacological and Physiological Aspects14. Cannabis, cannabinoids
and receptor responses; 15. Cannabidiol (CBD): abuse potential and
withdrawal; 16. 4,5- Dihydro-1H-pyrazole/3,4-Diarylpyrazoline class of
cannabinoid-1 (CB1R) receptor antagonists and their potential in medicinal
applications
IV. Neurobiology of cannabis17. Neurobiology of cannabis; 18. The
kynurenine pathway, neurobiology and cannabis misuse: a new narrative; 19.
Central nervous system cancers and use of cannabis and related products: an
updated narrative; 20. Chronic cannabis users: links with glutamate and
resting state connectivity; 21. Brain metabolic responses to cannabis use
in people with multiple sclerosis: Insights from [18F]-FDG positron
emission tomography and functional MRI; 22. Genetic Variation and Acute
Responses to Cannabis; 23. Cell Signaling of the CB1 Cannabinoid Receptor
via beta-arrestins, Cannabinoid Receptor Interacting Protein (CRIP1a) and
other regulatory proteins; 24. Cannabis and impact on memory: from in utero
to adults; 25. Central CB1 receptors and age-related changes: investigating
the effects of DELTA-9-tetrahydrocannabinol; 26. Alcohol, cannabis and
visual memory
V. Neurobiology of cannabinoids27. The role of Delta-FosB in the plasticity
of the cannabinoid system; 28. Functional profile of synthetic cannabinoid
receptor agonists: exploring cannabinoid and non-cannabinoid targets; 29.
Linking the G protein-coupled orphan receptor GPR55 to the cannabinoid
receptors (CB1 and CB2): a new narrative; 30. Proteomic analysis of
cannabinoids in human oligodendrocytes; 31. Cannabinoids and
endocannabinoid signaling at the basal forebrain cholinergic system; 32.
Cannabidiol (The major non-psychotropic cannabinoid in the cannabis plant)
and the PI3K/Akt pathway in the CNS; 33. Effects of cannabidiol and other
phytocannabinoids on ion channels;34. Cannabis, neurodevelopment and the
"two-hit hypothesis"
VI. New and synthetic cannabinoids35. Impact of tetrahydrocannabinol (THC )
and synthetic "spice"cannabinoids on nicotine use and abuse; 36. Synthetic
cannabinoids: how do they compare to DELTA9-tetrahydrocannabinol:
neurological effects and beyond
VII. Biomarkers, analysis and screening37. The DSM-5 criteria of cannabis
use disorder: methods and applications; 38. Cannabis and clinical high risk
for psychosis: monitoring and smartphones
VIII. Impact on non-neurological systems39. The impact of cannabis and
cannabinoids on the skin; 40. Cannabis consumption in reproduction and
teratogenicity; 41. Cannabis compounds and putative cytotoxicity: profile
of cancer cells
IX. Treatments, strategies and resources42. Motivational Interviewing for
Cannabis Use Disorders: a narrative review from research to practice; 43.
An Overview of Current Pharmacologic Interventions for Management of
Cannabis Withdrawal and the Evidence for Their Use; 44. Managing
cannabinoid hyperemesis syndrome in paediatrics: A new narrative review;
45. Gabapentinoids for the Treatment of Cannabis Use Disorder: A Focus on
Human Laboratory Research; 46. Treating psychosis in users of synthetic
cannabinoids
X. Resources47. Cannabis and Web based Resources
Medicinal Usage of Cannabis and CannabinoidsI. Setting the scene and
introductory chapters1. How medical cannabis may influence the future of
medicine; 2. Medical cannabis and cannabinoids: how best to extract
components from plant material; 3. Medicinal usage of cannabis and its
impact on mental health among cancer patients and survivors; 4. Cannabis
sativa as a traditional phytomedicine: a new narrative covering different
countries; 5. Medical use of cannabis in the middle east; 6. What medicinal
cannabis is used for: a focus on Canada; 7. New York perspectives of
medical cannabis laboratory analysis; 8. Epigenetic regulations on the
quality of clonal cannabis plants: secondary metabolites and profiles; 9.
Aberrant use of medicinal cannabis: theoretical and empirical
considerations; 10. Profile of older users of medical cannabis and
cannabinoids; 11. Use of cannabidiol oil by caregivers: a focus on
Alzheimer's disease; 12. Medicinal use of cannabis: adverse events as a
balanced perspective
II. Physiological aspects and metabolic aspects13. Physiopathology and use
of cannabinoids for fibrotic diseases; 14. Cannabinoids in inflammation and
atherosclerosis; 15. Targeting the CB(2) receptors and other
endocannabinoid elements to delay disease progression in cardiovascular
diseases; 16. BMI in cannabis users: regulation, mechanisms and public
health impact
III. Neurological, psychological and behavioural aspects17. Neuroprotection
by cannabis related products, cannabidiol and cannabigerol, and associated
mechanisms of action; 18. Cannabis terpenes as neuroprotective agents: a
focus on alpha-bisabolol; 19. Cannabidiol in medicinal usage of stress:
modelling investigations into cocaine; 20. Medicinal cannabis and
neurocognition impairment; 21. Genetic models of audiogenic seizures: what
they are and how cannabinoids and Cannabis-derived compounds can be used to
alleviate their symptoms - an updated narrative; 22. Addressing the
validity of cannabinoid therapy as an option for the treatment of substance
use disorder
IV. Pharmacological and cellular aspects23. Cannabidiolic acid (CBDA),
features and profiles: anti-hyperalgesic effects; 24. Cannabis-drug
interactions: implications for medicinal cannabis use; 25. Cannabinoid
receptor subtype 2 (CB2R): features and targets for medical applications;
26. Medical use of cannabidiol and impact on cancer cell viability; 27.
Anti-inflammatory and antioxidant and immunomodulatory effects of
phytocannabinoid -caryophyllene: A mechanistic overview
V. Symptom Control and Medicinal Uses28. Cancer patients and providers:
Attitudes and beliefs of cannabis and cannabinoids use as a treatment; 29.
CBD (cannabidiol) use in breast cancer chemotherapy; 30. Sleep: cannabis
and cannabinoids use; 31. Cannabis and cannabis related products and their
uses in aiding sexual health of men and women; 32. Symptom control in
palliative care settings: The role of cannabis-based medicines; 33.
Cannabidiol (CBD) Use in Fragile X Spectrum Disorders; 34. Hempseed
(Cannabis sativa) and ameliorative effects in hypercholesterolemia; 35.
Benzodiazepines and cannabis use; 36. Features of
(+)-trans-cannabidiol-2-hydroxy pentyland applications to disease: a focus
on usage in diabetic nephropathy; 37. Medical use of cannabis: applications
to Tourette syndrome; 38. Cannabinoids and their use in chronic non-cancer
pain: a new narrative review; 39. Endometriosis: features and potential
role of medical cannabis; 40. Cannabis usage for Crohn's disease and
ulcerative colitis: a narrative; 41. Medical cannabis and use in migraine;
42. Cannabidiol (CBD ) and potential in medicinal use in rheumatoid
arthritis; 43. Role of Cannabinoids in Glaucoma: Lowering Intraocular
Pressure or Neuroprotection; 44. Medicinal potential of anandamide as a
representative endocannabinoid and its effect at the cellular level in skin
VI. Resources45. Medical Cannabis and Resources
Neurobiology, Physiology, And The Endocannabinoid SystemI. Setting the
scene and introductory chapters1. Distribution of the endocannabinoid
system: linking signalling and development; 2. The endocannabinoid system,
immunomodulation, and LPS-induced inflammation; 3. Physiology of the
endocannabinoid systems: imaging and the use of positron emission
tomography (PET); 4. The endocannabinoid system and aging; 5. The
endocannabinoid system and post traumatic stress disorder (PTSD): a new
narrative
II. Neurobiology of the endocannabinoid system6. The protective effect of
the endocannabinoid system in neurotoxin induced damage to hippocampal
neurons: a focus on light and electron microscopy; 7. Endocannabinoid
Signaling and excitatory and inhibitory synapses; 8. The endocannabinoids
and potassium channels: an updated narrative; 9. Social interactions and
neural activity: linking cellular studies and endocannabinoid signalling;
10. Exercise and Parkinson's disease: linking in the cannabinoid type 1
(CB1) and type 2 (CB2), and mu-opioid receptors; 11. The endocannabinoids
system and endocannabinoid receptors in sleep; 12. Endocannabinoids and
inhalant misuse: neuropsychological aspects; 13. Fatty acid amide hydrolase
(FAAH) in substance use disorders: FAAH regulation and inhibition in
cannabis, alcohol, nicotine, stimulant, and opioid use disorders; 14.
Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and
human soluble epoxide hydrolase (sEH) enzyme inhibitors: interlinking the
endocannabinoid system; 15. WWL70: linking the hydrolyses
2-arachidonoylglycerol, endocannabinoid and eicosanoid pathways:
therapeutic potential and neurological disease; 16. Endocannabinoid
catabolic enzyme inhibitors and pain alleviation; 17. The endocannabinoid
system in health and disease: features in epilepsy; 18. The endocannabinoid
system and autoimmune demyelination: a focus on multiple sclerosis; 19.
Endocannabinoid signaling and the lateral habenula; 20. On the interplay
among endocannabinoid, noradrenergic and glucocorticoid systems: evidence
from aversive memory studies
III. Receptor biology and responses 21. Adenosine A2A-cannabinoid CB1
receptor heteromers in the brain: From trans-inhibition to
trans-activation; 22. Hippocampal CB1, CB2 receptors, the endocannabinoid
system and fear memory; 23. Beta-caryophyllene, the CB2 cannabinoid
receptor-specific agonists and wound healing; 24. The nigrostriatal
dopaminergic pathway: impact of WIN 55212-2 as a potent cannaboinoid
receptor agonist; 25. Peripheral cannabinoid receptor 1 antagonists and
impact on adipocytes; 26. Endocannabinoid system receptors in plasma
membranes : extraction, lipid rafts and the cortex; 27. Applications to
wound healing: cannabinoid receptor 1 antagonism and collagen deposition;
28. Role of the Transient Receptor Potential Vanilloid 1 (TRPV1), a
component of the endocannabinoid system, in anxiety, depression, and
cocaine addiction; 29. Allosteric modulators of the endocannabinoid system:
Org27569 and cannabinoid receptor 1 (CB1); 30. Naturally occurring
DELTA-9-tetrahydrocannabinol-derivatives and binding to CB1 and CB2
receptors: Linking in the endocannabinoid system
IV. Profiles and behaviour of selective endocannabinoids31. New cannabinoid
receptor type 1 and 2 agonists and applications to understanding the
endocannabinoid system; 32. Fatty acid amide hydrolase, the endocannabinoid
anandamide and neurological disease; 33. The endocannabinoid-system in the
immuno-biology of dendritic cells; 34. Palmitoylethanolamide and other
anandamide congeners in neuroinflammation-based disorders: linking in the
endocannabinoid system; 35. Endocannabinoid modulation of synaptic function
and behavior in the dorsomedial hypothalamus; 36. Key role of anandamide
and the endocannabinoid system in the modulation of cardio-renal
homeostasis; 37. The endocannabinoid system: Signaling and social
motivation
V. Exogenous, synthetic other compounds linking in the endocannabinoid
system38. Safety and toxicology of the dietary cannabinoid
beta-caryophyllene; 39. Synthetic cannabimimetics: an overview
VI. Compartive studies in non neurological systems 40. Non Neurological
Aspects of the Endocannabinoid System: Non Alcoholic Fatty Liver Disease;
41. Components of the Endocannabinoid system: Hepatic expression levels of
the cannabinoid receptors and microRNAs; 42. Tumour growth and the
endocannabinoid system: investigating CB2 agonists; 43. Linking
Endocannabinoid System, Palmitoylethanolamide and Sarcopenia in view of
therapeutic outcomes
VII. Resources44. Endocannabinoids and Resources
Cannabis Use, Neurobiology, Psychology, and TreatmentI. Setting the scene
and introductory chapters1. Metabolomics of the cannabis plant; 2. The
roots of Cannabis sativa: chemical and pharmacological profile; 3. Cannabis
related compounds in beverages and food; 4. The impact of prenatal cannabis
exposure: an overview; 5. Cannabinoid Genotoxicity and Congenital
Anomalies: A Convergent Synthesis of European and USA Datasets; 6. Cannabis
Genotoxicity and Cancer Incidence: A Highly Concordant Synthesis of
European and USA Datasets; 7. Cannabis, Cognitive impairment and Car Crash
risk
II. Cannabis usage8. Recreational cannabis use: a French perspective of
adverse effects; 9. Acute and chronic impact of cannabis on human
cognition; 10. Polydrug users, use of cannabidiol (CBD) and abuse
potential/Polydrug users, use of cannabinoids and abuse potential; 11.
Cannabis stigmas: a narrative of features; 12. Alterations of THC and CBD
ratios and impact on cognition; 13. When cannabis is used for medicinal
purposes: a focus on back pain
III. Pharmacological and Physiological Aspects14. Cannabis, cannabinoids
and receptor responses; 15. Cannabidiol (CBD): abuse potential and
withdrawal; 16. 4,5- Dihydro-1H-pyrazole/3,4-Diarylpyrazoline class of
cannabinoid-1 (CB1R) receptor antagonists and their potential in medicinal
applications
IV. Neurobiology of cannabis17. Neurobiology of cannabis; 18. The
kynurenine pathway, neurobiology and cannabis misuse: a new narrative; 19.
Central nervous system cancers and use of cannabis and related products: an
updated narrative; 20. Chronic cannabis users: links with glutamate and
resting state connectivity; 21. Brain metabolic responses to cannabis use
in people with multiple sclerosis: Insights from [18F]-FDG positron
emission tomography and functional MRI; 22. Genetic Variation and Acute
Responses to Cannabis; 23. Cell Signaling of the CB1 Cannabinoid Receptor
via beta-arrestins, Cannabinoid Receptor Interacting Protein (CRIP1a) and
other regulatory proteins; 24. Cannabis and impact on memory: from in utero
to adults; 25. Central CB1 receptors and age-related changes: investigating
the effects of DELTA-9-tetrahydrocannabinol; 26. Alcohol, cannabis and
visual memory
V. Neurobiology of cannabinoids27. The role of Delta-FosB in the plasticity
of the cannabinoid system; 28. Functional profile of synthetic cannabinoid
receptor agonists: exploring cannabinoid and non-cannabinoid targets; 29.
Linking the G protein-coupled orphan receptor GPR55 to the cannabinoid
receptors (CB1 and CB2): a new narrative; 30. Proteomic analysis of
cannabinoids in human oligodendrocytes; 31. Cannabinoids and
endocannabinoid signaling at the basal forebrain cholinergic system; 32.
Cannabidiol (The major non-psychotropic cannabinoid in the cannabis plant)
and the PI3K/Akt pathway in the CNS; 33. Effects of cannabidiol and other
phytocannabinoids on ion channels;34. Cannabis, neurodevelopment and the
"two-hit hypothesis"
VI. New and synthetic cannabinoids35. Impact of tetrahydrocannabinol (THC )
and synthetic "spice"cannabinoids on nicotine use and abuse; 36. Synthetic
cannabinoids: how do they compare to DELTA9-tetrahydrocannabinol:
neurological effects and beyond
VII. Biomarkers, analysis and screening37. The DSM-5 criteria of cannabis
use disorder: methods and applications; 38. Cannabis and clinical high risk
for psychosis: monitoring and smartphones
VIII. Impact on non-neurological systems39. The impact of cannabis and
cannabinoids on the skin; 40. Cannabis consumption in reproduction and
teratogenicity; 41. Cannabis compounds and putative cytotoxicity: profile
of cancer cells
IX. Treatments, strategies and resources42. Motivational Interviewing for
Cannabis Use Disorders: a narrative review from research to practice; 43.
An Overview of Current Pharmacologic Interventions for Management of
Cannabis Withdrawal and the Evidence for Their Use; 44. Managing
cannabinoid hyperemesis syndrome in paediatrics: A new narrative review;
45. Gabapentinoids for the Treatment of Cannabis Use Disorder: A Focus on
Human Laboratory Research; 46. Treating psychosis in users of synthetic
cannabinoids
X. Resources47. Cannabis and Web based Resources
Medicinal Usage of Cannabis and CannabinoidsI. Setting the scene and
introductory chapters1. How medical cannabis may influence the future of
medicine; 2. Medical cannabis and cannabinoids: how best to extract
components from plant material; 3. Medicinal usage of cannabis and its
impact on mental health among cancer patients and survivors; 4. Cannabis
sativa as a traditional phytomedicine: a new narrative covering different
countries; 5. Medical use of cannabis in the middle east; 6. What medicinal
cannabis is used for: a focus on Canada; 7. New York perspectives of
medical cannabis laboratory analysis; 8. Epigenetic regulations on the
quality of clonal cannabis plants: secondary metabolites and profiles; 9.
Aberrant use of medicinal cannabis: theoretical and empirical
considerations; 10. Profile of older users of medical cannabis and
cannabinoids; 11. Use of cannabidiol oil by caregivers: a focus on
Alzheimer's disease; 12. Medicinal use of cannabis: adverse events as a
balanced perspective
II. Physiological aspects and metabolic aspects13. Physiopathology and use
of cannabinoids for fibrotic diseases; 14. Cannabinoids in inflammation and
atherosclerosis; 15. Targeting the CB(2) receptors and other
endocannabinoid elements to delay disease progression in cardiovascular
diseases; 16. BMI in cannabis users: regulation, mechanisms and public
health impact
III. Neurological, psychological and behavioural aspects17. Neuroprotection
by cannabis related products, cannabidiol and cannabigerol, and associated
mechanisms of action; 18. Cannabis terpenes as neuroprotective agents: a
focus on alpha-bisabolol; 19. Cannabidiol in medicinal usage of stress:
modelling investigations into cocaine; 20. Medicinal cannabis and
neurocognition impairment; 21. Genetic models of audiogenic seizures: what
they are and how cannabinoids and Cannabis-derived compounds can be used to
alleviate their symptoms - an updated narrative; 22. Addressing the
validity of cannabinoid therapy as an option for the treatment of substance
use disorder
IV. Pharmacological and cellular aspects23. Cannabidiolic acid (CBDA),
features and profiles: anti-hyperalgesic effects; 24. Cannabis-drug
interactions: implications for medicinal cannabis use; 25. Cannabinoid
receptor subtype 2 (CB2R): features and targets for medical applications;
26. Medical use of cannabidiol and impact on cancer cell viability; 27.
Anti-inflammatory and antioxidant and immunomodulatory effects of
phytocannabinoid -caryophyllene: A mechanistic overview
V. Symptom Control and Medicinal Uses28. Cancer patients and providers:
Attitudes and beliefs of cannabis and cannabinoids use as a treatment; 29.
CBD (cannabidiol) use in breast cancer chemotherapy; 30. Sleep: cannabis
and cannabinoids use; 31. Cannabis and cannabis related products and their
uses in aiding sexual health of men and women; 32. Symptom control in
palliative care settings: The role of cannabis-based medicines; 33.
Cannabidiol (CBD) Use in Fragile X Spectrum Disorders; 34. Hempseed
(Cannabis sativa) and ameliorative effects in hypercholesterolemia; 35.
Benzodiazepines and cannabis use; 36. Features of
(+)-trans-cannabidiol-2-hydroxy pentyland applications to disease: a focus
on usage in diabetic nephropathy; 37. Medical use of cannabis: applications
to Tourette syndrome; 38. Cannabinoids and their use in chronic non-cancer
pain: a new narrative review; 39. Endometriosis: features and potential
role of medical cannabis; 40. Cannabis usage for Crohn's disease and
ulcerative colitis: a narrative; 41. Medical cannabis and use in migraine;
42. Cannabidiol (CBD ) and potential in medicinal use in rheumatoid
arthritis; 43. Role of Cannabinoids in Glaucoma: Lowering Intraocular
Pressure or Neuroprotection; 44. Medicinal potential of anandamide as a
representative endocannabinoid and its effect at the cellular level in skin
VI. Resources45. Medical Cannabis and Resources
Neurobiology, Physiology, And The Endocannabinoid SystemI. Setting the
scene and introductory chapters1. Distribution of the endocannabinoid
system: linking signalling and development; 2. The endocannabinoid system,
immunomodulation, and LPS-induced inflammation; 3. Physiology of the
endocannabinoid systems: imaging and the use of positron emission
tomography (PET); 4. The endocannabinoid system and aging; 5. The
endocannabinoid system and post traumatic stress disorder (PTSD): a new
narrative
II. Neurobiology of the endocannabinoid system6. The protective effect of
the endocannabinoid system in neurotoxin induced damage to hippocampal
neurons: a focus on light and electron microscopy; 7. Endocannabinoid
Signaling and excitatory and inhibitory synapses; 8. The endocannabinoids
and potassium channels: an updated narrative; 9. Social interactions and
neural activity: linking cellular studies and endocannabinoid signalling;
10. Exercise and Parkinson's disease: linking in the cannabinoid type 1
(CB1) and type 2 (CB2), and mu-opioid receptors; 11. The endocannabinoids
system and endocannabinoid receptors in sleep; 12. Endocannabinoids and
inhalant misuse: neuropsychological aspects; 13. Fatty acid amide hydrolase
(FAAH) in substance use disorders: FAAH regulation and inhibition in
cannabis, alcohol, nicotine, stimulant, and opioid use disorders; 14.
Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and
human soluble epoxide hydrolase (sEH) enzyme inhibitors: interlinking the
endocannabinoid system; 15. WWL70: linking the hydrolyses
2-arachidonoylglycerol, endocannabinoid and eicosanoid pathways:
therapeutic potential and neurological disease; 16. Endocannabinoid
catabolic enzyme inhibitors and pain alleviation; 17. The endocannabinoid
system in health and disease: features in epilepsy; 18. The endocannabinoid
system and autoimmune demyelination: a focus on multiple sclerosis; 19.
Endocannabinoid signaling and the lateral habenula; 20. On the interplay
among endocannabinoid, noradrenergic and glucocorticoid systems: evidence
from aversive memory studies
III. Receptor biology and responses 21. Adenosine A2A-cannabinoid CB1
receptor heteromers in the brain: From trans-inhibition to
trans-activation; 22. Hippocampal CB1, CB2 receptors, the endocannabinoid
system and fear memory; 23. Beta-caryophyllene, the CB2 cannabinoid
receptor-specific agonists and wound healing; 24. The nigrostriatal
dopaminergic pathway: impact of WIN 55212-2 as a potent cannaboinoid
receptor agonist; 25. Peripheral cannabinoid receptor 1 antagonists and
impact on adipocytes; 26. Endocannabinoid system receptors in plasma
membranes : extraction, lipid rafts and the cortex; 27. Applications to
wound healing: cannabinoid receptor 1 antagonism and collagen deposition;
28. Role of the Transient Receptor Potential Vanilloid 1 (TRPV1), a
component of the endocannabinoid system, in anxiety, depression, and
cocaine addiction; 29. Allosteric modulators of the endocannabinoid system:
Org27569 and cannabinoid receptor 1 (CB1); 30. Naturally occurring
DELTA-9-tetrahydrocannabinol-derivatives and binding to CB1 and CB2
receptors: Linking in the endocannabinoid system
IV. Profiles and behaviour of selective endocannabinoids31. New cannabinoid
receptor type 1 and 2 agonists and applications to understanding the
endocannabinoid system; 32. Fatty acid amide hydrolase, the endocannabinoid
anandamide and neurological disease; 33. The endocannabinoid-system in the
immuno-biology of dendritic cells; 34. Palmitoylethanolamide and other
anandamide congeners in neuroinflammation-based disorders: linking in the
endocannabinoid system; 35. Endocannabinoid modulation of synaptic function
and behavior in the dorsomedial hypothalamus; 36. Key role of anandamide
and the endocannabinoid system in the modulation of cardio-renal
homeostasis; 37. The endocannabinoid system: Signaling and social
motivation
V. Exogenous, synthetic other compounds linking in the endocannabinoid
system38. Safety and toxicology of the dietary cannabinoid
beta-caryophyllene; 39. Synthetic cannabimimetics: an overview
VI. Compartive studies in non neurological systems 40. Non Neurological
Aspects of the Endocannabinoid System: Non Alcoholic Fatty Liver Disease;
41. Components of the Endocannabinoid system: Hepatic expression levels of
the cannabinoid receptors and microRNAs; 42. Tumour growth and the
endocannabinoid system: investigating CB2 agonists; 43. Linking
Endocannabinoid System, Palmitoylethanolamide and Sarcopenia in view of
therapeutic outcomes
VII. Resources44. Endocannabinoids and Resources
and introductory chapters1. Metabolomics of the cannabis plant; 2. The
roots of Cannabis sativa: chemical and pharmacological profile; 3. Cannabis
related compounds in beverages and food; 4. The impact of prenatal cannabis
exposure: an overview; 5. Cannabinoid Genotoxicity and Congenital
Anomalies: A Convergent Synthesis of European and USA Datasets; 6. Cannabis
Genotoxicity and Cancer Incidence: A Highly Concordant Synthesis of
European and USA Datasets; 7. Cannabis, Cognitive impairment and Car Crash
risk
II. Cannabis usage8. Recreational cannabis use: a French perspective of
adverse effects; 9. Acute and chronic impact of cannabis on human
cognition; 10. Polydrug users, use of cannabidiol (CBD) and abuse
potential/Polydrug users, use of cannabinoids and abuse potential; 11.
Cannabis stigmas: a narrative of features; 12. Alterations of THC and CBD
ratios and impact on cognition; 13. When cannabis is used for medicinal
purposes: a focus on back pain
III. Pharmacological and Physiological Aspects14. Cannabis, cannabinoids
and receptor responses; 15. Cannabidiol (CBD): abuse potential and
withdrawal; 16. 4,5- Dihydro-1H-pyrazole/3,4-Diarylpyrazoline class of
cannabinoid-1 (CB1R) receptor antagonists and their potential in medicinal
applications
IV. Neurobiology of cannabis17. Neurobiology of cannabis; 18. The
kynurenine pathway, neurobiology and cannabis misuse: a new narrative; 19.
Central nervous system cancers and use of cannabis and related products: an
updated narrative; 20. Chronic cannabis users: links with glutamate and
resting state connectivity; 21. Brain metabolic responses to cannabis use
in people with multiple sclerosis: Insights from [18F]-FDG positron
emission tomography and functional MRI; 22. Genetic Variation and Acute
Responses to Cannabis; 23. Cell Signaling of the CB1 Cannabinoid Receptor
via beta-arrestins, Cannabinoid Receptor Interacting Protein (CRIP1a) and
other regulatory proteins; 24. Cannabis and impact on memory: from in utero
to adults; 25. Central CB1 receptors and age-related changes: investigating
the effects of DELTA-9-tetrahydrocannabinol; 26. Alcohol, cannabis and
visual memory
V. Neurobiology of cannabinoids27. The role of Delta-FosB in the plasticity
of the cannabinoid system; 28. Functional profile of synthetic cannabinoid
receptor agonists: exploring cannabinoid and non-cannabinoid targets; 29.
Linking the G protein-coupled orphan receptor GPR55 to the cannabinoid
receptors (CB1 and CB2): a new narrative; 30. Proteomic analysis of
cannabinoids in human oligodendrocytes; 31. Cannabinoids and
endocannabinoid signaling at the basal forebrain cholinergic system; 32.
Cannabidiol (The major non-psychotropic cannabinoid in the cannabis plant)
and the PI3K/Akt pathway in the CNS; 33. Effects of cannabidiol and other
phytocannabinoids on ion channels;34. Cannabis, neurodevelopment and the
"two-hit hypothesis"
VI. New and synthetic cannabinoids35. Impact of tetrahydrocannabinol (THC )
and synthetic "spice"cannabinoids on nicotine use and abuse; 36. Synthetic
cannabinoids: how do they compare to DELTA9-tetrahydrocannabinol:
neurological effects and beyond
VII. Biomarkers, analysis and screening37. The DSM-5 criteria of cannabis
use disorder: methods and applications; 38. Cannabis and clinical high risk
for psychosis: monitoring and smartphones
VIII. Impact on non-neurological systems39. The impact of cannabis and
cannabinoids on the skin; 40. Cannabis consumption in reproduction and
teratogenicity; 41. Cannabis compounds and putative cytotoxicity: profile
of cancer cells
IX. Treatments, strategies and resources42. Motivational Interviewing for
Cannabis Use Disorders: a narrative review from research to practice; 43.
An Overview of Current Pharmacologic Interventions for Management of
Cannabis Withdrawal and the Evidence for Their Use; 44. Managing
cannabinoid hyperemesis syndrome in paediatrics: A new narrative review;
45. Gabapentinoids for the Treatment of Cannabis Use Disorder: A Focus on
Human Laboratory Research; 46. Treating psychosis in users of synthetic
cannabinoids
X. Resources47. Cannabis and Web based Resources
Medicinal Usage of Cannabis and CannabinoidsI. Setting the scene and
introductory chapters1. How medical cannabis may influence the future of
medicine; 2. Medical cannabis and cannabinoids: how best to extract
components from plant material; 3. Medicinal usage of cannabis and its
impact on mental health among cancer patients and survivors; 4. Cannabis
sativa as a traditional phytomedicine: a new narrative covering different
countries; 5. Medical use of cannabis in the middle east; 6. What medicinal
cannabis is used for: a focus on Canada; 7. New York perspectives of
medical cannabis laboratory analysis; 8. Epigenetic regulations on the
quality of clonal cannabis plants: secondary metabolites and profiles; 9.
Aberrant use of medicinal cannabis: theoretical and empirical
considerations; 10. Profile of older users of medical cannabis and
cannabinoids; 11. Use of cannabidiol oil by caregivers: a focus on
Alzheimer's disease; 12. Medicinal use of cannabis: adverse events as a
balanced perspective
II. Physiological aspects and metabolic aspects13. Physiopathology and use
of cannabinoids for fibrotic diseases; 14. Cannabinoids in inflammation and
atherosclerosis; 15. Targeting the CB(2) receptors and other
endocannabinoid elements to delay disease progression in cardiovascular
diseases; 16. BMI in cannabis users: regulation, mechanisms and public
health impact
III. Neurological, psychological and behavioural aspects17. Neuroprotection
by cannabis related products, cannabidiol and cannabigerol, and associated
mechanisms of action; 18. Cannabis terpenes as neuroprotective agents: a
focus on alpha-bisabolol; 19. Cannabidiol in medicinal usage of stress:
modelling investigations into cocaine; 20. Medicinal cannabis and
neurocognition impairment; 21. Genetic models of audiogenic seizures: what
they are and how cannabinoids and Cannabis-derived compounds can be used to
alleviate their symptoms - an updated narrative; 22. Addressing the
validity of cannabinoid therapy as an option for the treatment of substance
use disorder
IV. Pharmacological and cellular aspects23. Cannabidiolic acid (CBDA),
features and profiles: anti-hyperalgesic effects; 24. Cannabis-drug
interactions: implications for medicinal cannabis use; 25. Cannabinoid
receptor subtype 2 (CB2R): features and targets for medical applications;
26. Medical use of cannabidiol and impact on cancer cell viability; 27.
Anti-inflammatory and antioxidant and immunomodulatory effects of
phytocannabinoid -caryophyllene: A mechanistic overview
V. Symptom Control and Medicinal Uses28. Cancer patients and providers:
Attitudes and beliefs of cannabis and cannabinoids use as a treatment; 29.
CBD (cannabidiol) use in breast cancer chemotherapy; 30. Sleep: cannabis
and cannabinoids use; 31. Cannabis and cannabis related products and their
uses in aiding sexual health of men and women; 32. Symptom control in
palliative care settings: The role of cannabis-based medicines; 33.
Cannabidiol (CBD) Use in Fragile X Spectrum Disorders; 34. Hempseed
(Cannabis sativa) and ameliorative effects in hypercholesterolemia; 35.
Benzodiazepines and cannabis use; 36. Features of
(+)-trans-cannabidiol-2-hydroxy pentyland applications to disease: a focus
on usage in diabetic nephropathy; 37. Medical use of cannabis: applications
to Tourette syndrome; 38. Cannabinoids and their use in chronic non-cancer
pain: a new narrative review; 39. Endometriosis: features and potential
role of medical cannabis; 40. Cannabis usage for Crohn's disease and
ulcerative colitis: a narrative; 41. Medical cannabis and use in migraine;
42. Cannabidiol (CBD ) and potential in medicinal use in rheumatoid
arthritis; 43. Role of Cannabinoids in Glaucoma: Lowering Intraocular
Pressure or Neuroprotection; 44. Medicinal potential of anandamide as a
representative endocannabinoid and its effect at the cellular level in skin
VI. Resources45. Medical Cannabis and Resources
Neurobiology, Physiology, And The Endocannabinoid SystemI. Setting the
scene and introductory chapters1. Distribution of the endocannabinoid
system: linking signalling and development; 2. The endocannabinoid system,
immunomodulation, and LPS-induced inflammation; 3. Physiology of the
endocannabinoid systems: imaging and the use of positron emission
tomography (PET); 4. The endocannabinoid system and aging; 5. The
endocannabinoid system and post traumatic stress disorder (PTSD): a new
narrative
II. Neurobiology of the endocannabinoid system6. The protective effect of
the endocannabinoid system in neurotoxin induced damage to hippocampal
neurons: a focus on light and electron microscopy; 7. Endocannabinoid
Signaling and excitatory and inhibitory synapses; 8. The endocannabinoids
and potassium channels: an updated narrative; 9. Social interactions and
neural activity: linking cellular studies and endocannabinoid signalling;
10. Exercise and Parkinson's disease: linking in the cannabinoid type 1
(CB1) and type 2 (CB2), and mu-opioid receptors; 11. The endocannabinoids
system and endocannabinoid receptors in sleep; 12. Endocannabinoids and
inhalant misuse: neuropsychological aspects; 13. Fatty acid amide hydrolase
(FAAH) in substance use disorders: FAAH regulation and inhibition in
cannabis, alcohol, nicotine, stimulant, and opioid use disorders; 14.
Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and
human soluble epoxide hydrolase (sEH) enzyme inhibitors: interlinking the
endocannabinoid system; 15. WWL70: linking the hydrolyses
2-arachidonoylglycerol, endocannabinoid and eicosanoid pathways:
therapeutic potential and neurological disease; 16. Endocannabinoid
catabolic enzyme inhibitors and pain alleviation; 17. The endocannabinoid
system in health and disease: features in epilepsy; 18. The endocannabinoid
system and autoimmune demyelination: a focus on multiple sclerosis; 19.
Endocannabinoid signaling and the lateral habenula; 20. On the interplay
among endocannabinoid, noradrenergic and glucocorticoid systems: evidence
from aversive memory studies
III. Receptor biology and responses 21. Adenosine A2A-cannabinoid CB1
receptor heteromers in the brain: From trans-inhibition to
trans-activation; 22. Hippocampal CB1, CB2 receptors, the endocannabinoid
system and fear memory; 23. Beta-caryophyllene, the CB2 cannabinoid
receptor-specific agonists and wound healing; 24. The nigrostriatal
dopaminergic pathway: impact of WIN 55212-2 as a potent cannaboinoid
receptor agonist; 25. Peripheral cannabinoid receptor 1 antagonists and
impact on adipocytes; 26. Endocannabinoid system receptors in plasma
membranes : extraction, lipid rafts and the cortex; 27. Applications to
wound healing: cannabinoid receptor 1 antagonism and collagen deposition;
28. Role of the Transient Receptor Potential Vanilloid 1 (TRPV1), a
component of the endocannabinoid system, in anxiety, depression, and
cocaine addiction; 29. Allosteric modulators of the endocannabinoid system:
Org27569 and cannabinoid receptor 1 (CB1); 30. Naturally occurring
DELTA-9-tetrahydrocannabinol-derivatives and binding to CB1 and CB2
receptors: Linking in the endocannabinoid system
IV. Profiles and behaviour of selective endocannabinoids31. New cannabinoid
receptor type 1 and 2 agonists and applications to understanding the
endocannabinoid system; 32. Fatty acid amide hydrolase, the endocannabinoid
anandamide and neurological disease; 33. The endocannabinoid-system in the
immuno-biology of dendritic cells; 34. Palmitoylethanolamide and other
anandamide congeners in neuroinflammation-based disorders: linking in the
endocannabinoid system; 35. Endocannabinoid modulation of synaptic function
and behavior in the dorsomedial hypothalamus; 36. Key role of anandamide
and the endocannabinoid system in the modulation of cardio-renal
homeostasis; 37. The endocannabinoid system: Signaling and social
motivation
V. Exogenous, synthetic other compounds linking in the endocannabinoid
system38. Safety and toxicology of the dietary cannabinoid
beta-caryophyllene; 39. Synthetic cannabimimetics: an overview
VI. Compartive studies in non neurological systems 40. Non Neurological
Aspects of the Endocannabinoid System: Non Alcoholic Fatty Liver Disease;
41. Components of the Endocannabinoid system: Hepatic expression levels of
the cannabinoid receptors and microRNAs; 42. Tumour growth and the
endocannabinoid system: investigating CB2 agonists; 43. Linking
Endocannabinoid System, Palmitoylethanolamide and Sarcopenia in view of
therapeutic outcomes
VII. Resources44. Endocannabinoids and Resources